Country: United Kingdom
Language: English
Source: VMD (Veterinary Medicines Directorate)
Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus
Virbac
QI07AD04
Canine adenovirus, Canine distemper virus, Canine parainfluenza virus, Canine parvovirus
Lyophilisate and solvent for suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Live Viral Vaccine
Authorized
2016-09-08
Revised: December 2023 AN: 03634/2022 & 03635/2022 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT CANIXIN DHPPi lyophilisate and solvent for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains: ACTIVE SUBSTANCES: Lyophilisate Live attenuated canine distemper virus (CDV) - Lederle strain 10 3.0 - 10 4.9 CCID 50 * Live attenuated canine adenovirus type 2 (CAV-2) - Manhattan strain 10 4.0 - 10 6.0 CCID 50 * Live attenuated canine parvovirus (CPV) - CPV780916 strain 10 5.0 - 10 6.8 CCID 50 * Live attenuated canine parainfluenza virus (CPIV) - Manhattan strain 10 5.0 - 10 6.9 CCID 50 * * Cell culture infectious dose 50% Solvent Water for injections 1 ml EXCIPIENTS: For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and solvent for suspension for injection. Lyophilisate: White lyophilisate. Solvent: Colourless liquid. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dog 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For active immunisation of dogs from 8 weeks of age to: - prevent mortality and clinical signs caused by canine distemper virus; - prevent mortality and clinical signs caused by canine adenovirus type 1; Revised: December 2023 AN: 03634/2022 & 03635/2022 Page 2 of 6 - prevent clinical signs and mortality and reduce excretion caused by canine parvovirus in challenge studies performed with a CPV-2b strain; - prevent clinical signs and reduce excretion caused by canine parvovirus in a challenge study performed with a CPV-2c strain - reduce respiratory clinical signs and viral excretion caused by canine parainfluenza virus and canine adenovirus type 2; Onset of immunity: The onset of immunity has been demonstrated: • From 3 weeks after the primary vaccination for CDV, CAV2 and CPV • From 4 weeks after the primary vaccination for CPiV and CAV-1 Duration of immunity: After the primary vaccination course, the duration of immunity lasts for one year for all components. In the dur Read the complete document